| アブストラクト | Background Multimorbidity and polypharmacy are common in older people. Despite the existence of quality criteria for medication use among this population, there is little guidance for managing the complex pharmacological arsenal in a multimorbidity context. Objective To establish consensus on benefits, risks and impacts on quality of life of medications used in an older adult with three chronic diseases that require complex pharmacotherapy. Setting International experts in pharmacology. Method A panel of experts responded to three rounds of a Delphi survey. They assessed the benefits, risks and positive impacts on quality of life of 50 different medications or medication classes that could be used by a hypothetical multimorbid older patient aged 65-75 years, with type 2 diabetes, heart failure and chronic obstructive pulmonary disease. Each aspect was evaluated on a 5-level Likert scale. Main outcome measure Percentage of agreement on each of the three aspects for all medication. Results Consensus was reached on 95% of items (166/174). Only two medication classes were associated with both the highest category of benefits and positive impacts on quality of life, and the lowest risk category: long-acting anticholinergics and long-acting beta-2-agonists. Nine other medications/classes of medications were categorized within the highest benefits level (metformin, DPP-4-inhibitors, short-acting beta-2-agonists, ACE inhibitors, beta-blockers, warfarin, non-vitamin K oral anticoagulants, nitrates and acetaminophen). Fifteen medications were included in the highest level of risks, among which warfarin and Non-vitamin K oral anticoagulants. Conclusions Medications recommended in clinical guidelines for individual diseases are generally considered positive for multimorbid older patients. Nevertheless, a non-negligible number of medications was deemed negative or very negative by our panelists. For multimorbid patients, individualizing treatment according to their preferences seems of utmost importance. |
|---|
| 組織名 | Department of Social and Preventive Medicine, Laval University, Quebec, Canada.;Caroline.Sirois@fmed.ulaval.ca.;Centre d'excellence sur le vieillissement de Quebec, CIUSSS-CN, Hopital;St-Sacrement, Local L2-28, 1050, Chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada.;Centre de recherche sur les soins et les services de premiere ligne de;l'Universite Laval, Quebec, Canada. Caroline.Sirois@fmed.ulaval.ca.;Department of Nursing, UQAR, Levis, Canada.;Faculty of Medicine, Laval University, Quebec, Canada.;Service de Pharmacologie, Toxicologie et Pharmacovigilance, Centre Regional de;Pharmacovigilance, de Pharmacoepidemiologie et d'information sur les medicaments,;Centre Hospitalier Universitaire de Limoges, Limoges, France.;Faculty of Medicine, Limoges University, Limoges, France.;INSERM 1248, Limoges University, Limoges, France.;Department of Management, UQAR, Levis, Canada. |
|---|
